Literature DB >> 15006712

Unlicensed and off-label drug use in children: implications for safety.

Imti Choonara.   

Abstract

Throughout the world, many drugs prescribed for children are used in an off-label or unlicensed manner. The incidence of unlicensed and off-label drug prescriptions appears to be greatest in critically ill neonates and children and lowest in the general population. The risk associated with unlicensed and off-label drug use appears to be greater than for prescribing in accordance with the product licence. Health professionals, however, usually have no alternative but to use unlicensed and off-label medicines. More clinical trials for medicines in children are required to provide the evidence base for safe and effective drug prescribing.

Entities:  

Mesh:

Year:  2004        PMID: 15006712     DOI: 10.1517/eods.3.2.81.27342

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  17 in total

1.  Off label and unlicensed drugs use in paediatric cardiology.

Authors:  M Bajcetic; M Jelisavcic; J Mitrovic; N Divac; S Simeunovic; R Samardzic; R Gorodischer
Journal:  Eur J Clin Pharmacol       Date:  2005-09-08       Impact factor: 2.953

2.  A mechanistic approach for the scaling of clearance in children.

Authors:  Andrea N Edginton; Walter Schmitt; Barbara Voith; Stefan Willmann
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 3.  Innovative clinical trial design for pediatric therapeutics.

Authors:  Matthew M Laughon; Daniel K Benjamin; Edmund V Capparelli; Gregory L Kearns; Katherine Berezny; Ian M Paul; Kelly Wade; Jeff Barrett; Phillip Brian Smith; Michael Cohen-Wolkowiez
Journal:  Expert Rev Clin Pharmacol       Date:  2011-09       Impact factor: 5.045

4.  Hospital pharmacists' perceived beliefs and responsibilities in indication-based off-label prescribing.

Authors:  Ramsankar Basak; David J McCaffrey
Journal:  Int J Clin Pharm       Date:  2017-12-04

5.  Development and evaluation of a generic physiologically based pharmacokinetic model for children.

Authors:  Andrea N Edginton; Walter Schmitt; Stefan Willmann
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

6.  Dose-Banding of Intravenous Piperacillin-Tazobactam in Pediatric Surgical Inpatients.

Authors:  Indrajit S Karande; Zoy Goff; Jacqueline Kewley; Shailender Mehta; Thomas Snelling
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Sep-Oct

Review 7.  Ethical considerations for pharmacogenomic testing in pediatric clinical care and research.

Authors:  Cassandra Moran; Courtney D Thornburg; Raymond C Barfield
Journal:  Pharmacogenomics       Date:  2011-06       Impact factor: 2.533

8.  Off-label prescribing in a French hospital.

Authors:  Audrey Cras; Marie-Agnès Conscience; Gérald Rajzbaum; Agnès Lillo-Le Louët; Nathalie Lopez; Isabelle Tersen; Yvonnick Bezie
Journal:  Pharm World Sci       Date:  2006-12-12

9.  Diuretic exposure in premature infants from 1997 to 2011.

Authors:  Matthew M Laughon; Kim Chantala; Sofia Aliaga; Amy H Herring; Christoph P Hornik; Rachel Hughes; Reese H Clark; P Brian Smith
Journal:  Am J Perinatol       Date:  2014-05-06       Impact factor: 3.079

10.  Population pharmacokinetics of piperacillin using scavenged samples from preterm infants.

Authors:  Michael Cohen-Wolkowiez; Daniel K Benjamin; Ashley Ross; Laura P James; Janice E Sullivan; Michele C Walsh; Arlene Zadell; Nancy Newman; Nicole R White; Angela D M Kashuba; Daniele Ouellet
Journal:  Ther Drug Monit       Date:  2012-06       Impact factor: 3.681

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.